Trial Profile

A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sucroferric oxyhydroxide (Primary)
Indications Hyperphosphataemia
Focus Adverse reactions; Registrational
Sponsors Kissei Pharmaceutical

Most Recent Events

30 Sep 2015 According to Kissei Pharmaceutical media release, new drug application for sucroferric oxyhydroxide for treatment of hyperphosphatemia has been approved by the Ministry of Health, Labour and Welfare in Japan.
19 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
09 Jun 2014 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com